Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).

@article{Finn2011PhaseIS,
  title={Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).},
  author={Richard S. Finn and Ronnie Tung-ping Poon and Tsz-kok Yau and H J Klumpen and Lee-may Chen and Yoon-koo Kang and Taewon Kim and Carlos G{\'o}mez-Mart{\'i}n and Carlos Rodr{\'i}guez-Lope and Tiffany Kunz and Thierry Paquet and K Asubonteng and Robert E Winkler and Oezlem Anak and Dalila B Sellami and Jordi Bruix},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4074}
}
4074 Background: The PI3K/Akt/mTOR pathway, a key regulator of cellular proliferation and angiogenesis, has emerged as a contributor to hepatocarcinogenesis. Everolimus, an mTOR inhibitor, exhibits antineoplastic activity in preclinical and experimental models of HCC. Sorafenib, a multi-tyrosine kinase (including Raf) inhibitor, is the only targeted therapy demonstrating a survival benefit and approved for first-line treatment in patients with unresectable HCC. Enhanced efficacy may be achieved… CONTINUE READING